URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Anton Porsteinsson

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentPsychiatry
AddressMonroe Community Hospital
435 East Henrietta Road
Psychiatry
Rochester NY 14620
 
 Awards And Honors
1981     Thorvaldur Thoroddsens Memorial Award  | Reykjavik College
1981     P.O. Christensens Memorial Award  | Reykjavik College
1992     Consultation-Liaison Award  | University of Rochester School of Medicine and Dentistry
1993     Carl Albert Jaenike Award  | The Genesee Valley Psychiatric Assoc. & the Dept. of Psychiatry
1993     Residents' Recognition Award  | University of Rochester School of Medicine and Dentistry
1997     The Helga Jonsdottir and Sigurlidi Kristjansson Memorial Award  | NIMH/American Association of Geriatric Psychiatry
1999     Summer Research Institute Fellowship  | NIMH/American Assoc. of Geriatric Psychiatry
2007     Listed in editions of Who's Who in America
2009     Dr. John Baum Award, University of Rochester School of Medicine and Dentistry
2010     Listed in editions of Distinguished Professionals
2010     Listed in editions of The Global Directory of Who's Who
 
 Selected Publications
List All   |   Timeline
  1. Flynn Longmire CV, Drye LT, Frangakis CE, Martin BK, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's disease study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.
    View in: PubMed
  2. Chapman RM, Porsteinsson AP, Gardner MN, Mapstone M, McCrary JW, Sandoval TC, Guillily MD, Reilly LA, Degrush E. The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion. Curr Alzheimer Res. 2013 Sep; 10(7):732-41.
    View in: PubMed
  3. Porsteinsson AP, Hasselberg MJ. The law of diminishing intent: getting excited about apathy. J Clin Psychiatry. 2013 Aug; 74(8):817-8.
    View in: PubMed
  4. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctôt KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Ballard C, Khin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimers Dement. 2013 Sep; 9(5):602-8.
    View in: PubMed
  5. Chapman RM, Porsteinsson AP, Gardner MN, Mapstone M, McCrary JW, Sandoval TC, Guillily MD, Degrush E, Reilly LA. C145 as a short-latency electrophysiological index of cognitive compensation in Alzheimer's disease. J Alzheimers Dis. 2013 Jan 1; 33(1):55-68.
    View in: PubMed
  6. Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44.
    View in: PubMed
  7. Dar-Nimrod I, Chapman BP, Franks P, Robbins J, Porsteinsson A, Mapstone M, Duberstein PR. Personality factors moderate the associations between apolipoprotein genotype and cognitive function as well as late onset Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1026-35.
    View in: PubMed
  8. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71.
    View in: PubMed
  9. Sabbagh M, Porsteinsson AP, Nair A, Adem A. Novel therapeutics in Alzheimer's disease. Int J Alzheimers Dis. 2012; 2012:207969.
    View in: PubMed
  10. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6; 109(10):3985-90.
    View in: PubMed
  11. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012 Mar; 11(3):241-9.
    View in: PubMed
  12. Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30.
    View in: PubMed
  13. Dar-Nimrod I, Chapman BP, Robbins JA, Porsteinsson A, Mapstone M, Duberstein PR. Gene by neuroticism interaction and cognitive function among older adults. Int J Geriatr Psychiatry. 2012 Nov; 27(11):1147-54.
    View in: PubMed
  14. Porsteinsson AP, Makino KM. Depression in older adults: is there another reason to worry? J Clin Psychiatry. 2012 Jan; 73(1):113-4.
    View in: PubMed
  15. Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Dimitri A. Sertraline for the treatment of depression in Alzheimer disease: genetic influences. J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8.
    View in: PubMed
  16. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 27; 77(13):1253-62.
    View in: PubMed
  17. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61.
    View in: PubMed
  18. Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Munro CA, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83.
    View in: PubMed
  19. Chapman RM, Mapstone M, Porsteinsson AP, Gardner MN, McCrary JW, DeGrush E, Reilly LA, Sandoval TC, Guillily MD. Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses. J Clin Exp Neuropsychol. 2010 Oct; 32(8):793-808.
    View in: PubMed
  20. Chapman RM, Mapstone M, McCrary JW, Gardner MN, Porsteinsson A, Sandoval TC, Guillily MD, Degrush E, Reilly LA. Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods. J Clin Exp Neuropsychol. 2011 Feb; 33(2):187-99.
    View in: PubMed
  21. de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, Taragano F, Kremer J, Brugnolo A, Porsteinsson AP, Geda YE, Brodaty H, Gazdag G, Cummings J, Lyketsos C. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010 Sep; 22(6):984-94.
    View in: PubMed
  22. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40.
    View in: PubMed
  23. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45.
    View in: PubMed
  24. Boyle LL, Porsteinsson AP, Cui X, King DA, Lyness JM. Depression predicts cognitive disorders in older primary care patients. J Clin Psychiatry. 2010 Jan; 71(1):74-9.
    View in: PubMed
  25. Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am J Geriatr Psychiatry. 2009 Sep; 17(9):752-9.
    View in: PubMed
  26. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010 Mar 15; 67(6):505-12.
    View in: PubMed
  27. Porsteinsson AP, Cosman KM. Grumpy old men (and women): mere hassle or meaningful clinical evidence? J Clin Psychiatry. 2009 Apr; 70(4):582-3.
    View in: PubMed
  28. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008 Nov 18; 71(21):1702-8.
    View in: PubMed
  29. Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008 Jul; 16(7):537-50.
    View in: PubMed
  30. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008 Jul; 65(7):896-905.
    View in: PubMed
  31. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.
    View in: PubMed
  32. Cosman KM, Boyle LL, Porsteinsson AP. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother. 2007 Feb; 8(2):203-14.
    View in: PubMed
  33. Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG. Design of Depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30.
    View in: PubMed
  34. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006 Feb 28; 66(4):602-4.
    View in: PubMed
  35. Porsteinsson AP. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging. 2006; 23(11):877-86.
    View in: PubMed
  36. Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A, Tariot PN. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. Curr Alzheimer Res. 2005 Dec; 2(5):553-8.
    View in: PubMed
  37. Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005 Nov; 13(11):942-9.
    View in: PubMed
  38. Rosenberg PB, Onyike CU, Katz IR, Porsteinsson AP, Mintzer JE, Schneider LS, Rabins PV, Meinert CL, Martin BK, Lyketsos CG. Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'. Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27.
    View in: PubMed
  39. Schneider LS, Porsteinsson AP, Peskin ER, Pfeiffer EA. Choosing treatment for Alzheimer's patients and their caregivers. Geriatrics. 2003 Aug; 58 Suppl 1:3-18, 23; quiz 19-22.
    View in: PubMed
  40. Porsteinsson AP, Tariot PN, Jakimovich LJ, Kowalski N, Holt C, Erb R, Cox C. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry. 2003 Jul-Aug; 11(4):434-40.
    View in: PubMed
  41. Tune LE, Porsteinsson A, Weinberg A. Dementia management: regulations, rules, and research. J Am Med Dir Assoc. 2003 Jul-Aug; 4(4 Suppl):H13-6.
    View in: PubMed
  42. Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev. 2002 Dec 7; 54(12):1567-77.
    View in: PubMed
  43. Nelson JC, Tune LE, Daiello LA, Porsteinsson A. Interactive grand rounds: mood stabilizers in dementia. Geriatrics. 2002 Sep; 57(9):suppl 2-5.
    View in: PubMed
  44. Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider LS. Pharmacologic therapy for behavioral symptoms of Alzheimer's disease. Clin Geriatr Med. 2001 May; 17(2):359-76.
    View in: PubMed
  45. Noviasky JA, Porsteinsson AP, Lee YH. Second generation anticonvulsant medications: their use in children. J Sch Nurs. 2001 Apr; 17(2):103-11.
    View in: PubMed
  46. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001; 9(1):58-66.
    View in: PubMed
  47. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000 Jun 27; 54(12):2269-76.
    View in: PubMed
  48. Tariot PN, Schneider L, Porsteinsson AP. Treating Alzheimer's disease. Pharmacologic options now and in the near future. Postgrad Med. 1997 Jun; 101(6):73-6, 81, 84 passim.
    View in: PubMed
  49. Tariot P, Gaile SE, Castelli NA, Porsteinsson AP. Treatment of agitation in dementia. New Dir Ment Health Serv. 1997; (76):109-23.
    View in: PubMed
  50. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry. 1997; 5(4):344-51.
    View in: PubMed
  51. Porsteinsson A, Duberstein PR, Conwell Y, Cox C, Forbes N, Caine ED. Suicide and alcoholism. Distinguishing alcoholic patients with and without comorbid drug abuse. Am J Addict. 1997; 6(4):304-10.
    View in: PubMed
  52. Woolf PD, Nichols D, Porsteinsson A, Boulay R. Thyroid evaluation of hospitalized psychiatric patients: the role of TSH screening for thyroid dysfunction. Thyroid. 1996 Oct; 6(5):451-6.
    View in: PubMed

Visualizations


Porsteinsson's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department